Beijing-based Brian Yang is a senior writer in charge of overall China coverage within the APAC Pharma news team. A veteran journalist, he has written extensively on pharmaceutical R&D, regulatory affairs and market access for PharmAsia News. Brian’s intimate industry knowledge and in-depth analysis has won wide praise and helped secure exclusive interviews with top biopharma executives.
He has led a team of writers to provide industry-leading coverage on key issues such as multi-regional clinical trials, priority reviews and go-to-market strategies in a highly-dynamic and fast-changing market, with the on-the-ground coverage consistently ranked among the top-read in PharmAsia News.
Prior to joining Informa, Brian worked as a foreign affairs correspondent for two TV networks and web editor for an international radio station. Trilingual in Mandarin Chinese, English and Japanese, he obtained his BA degree from China and an MA degree from Japan.
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Brian Yang
Recent biotech investment deals involving WuXi, Oncologie and Siranomics show Chinese investors are becoming increasingly bold and savvy in betting on innovative assets both inside and outside the country.
Eight drugs from foreign multinationals, including Amgen’s Rapatha, Takeda’s Takecab, Sanofi’s Aubagio and UCB’s Cimzia, are among 12 products awarded priority new drug approval reviews in China under a scheme to speed up approvals and patient access that is also benefiting some domestic players.
The coming of June has brought new executives at Daiichi Sankyo, UCB, ViiV in Japan and ZAI Lab in China.
The first ever agency devoted to medical insurance in China, MISA is potentially on track to become a major player in drug price negotiation, reimbursement level setting, and drug and device bidding in the country.
Recent deals linking Chinese and foreign firms indicate new and bolder views on China’s prospects for cutting-edge oncology and rare disease treatments, helped by recent regulatory changes, but a mix of factors is still at play, veteran executives say.
Largely different from the US and EU, China is tackling rare diseases with a first-ever official list of 121 conditions for now, which could be a major milestone for orphan drug developers, some experts say.